BIGBEAR
PHARMACEUTICAL
Enasidenib's innovative therapy offers a new treatment option for AML patients who are unresponsive to or experience relapse with conventional therapies.
AuthenticGuaranteeFast DeliveryPrivacy Enasidenib dosage and administration must strictly follow the doctor's instructions and be administered under the guidance of a professional physi···【More】
Update: 24 Mar,2026Source: BigbearViews: 97
Enasidenib is the first FDA-approved treatment for acute myeloid leukemia (AML) targeting IDH2 mutations, indicated for relapsed or refractory adult p···【More】
Update: 18 Mar,2026Source: BigbearViews: 97
Precautions for EnxidipineEnxidipine is used for relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation. An FDA-approved diagnostic···【More】
Update: 18 Mar,2026Source: BigbearViews: 94
August 1, 2017 – The U.S. Food and Drug Administration (FDA) approved enasidenib for the treatment of adult patients with relapsed or refractory acute···【More】
Update: 10 Mar,2026Source: BigbearViews: 96
In addition to the expected therapeutic effects, some adverse reactions may occur when receiving enasidenib treatment. While not all side effects will···【More】
Update: 10 Mar,2026Source: BigbearViews: 96
On November 29, 2018, the U.S. Food and Drug Administration (FDA) warned that symptoms of differentiation syndrome, a life-threatening side effect of ···【More】
Update: 10 Mar,2026Source: BigbearViews: 95
On November 29, 2018, the U.S. Food and Drug Administration (FDA) warned that symptoms of differentiation syndrome, a life-threatening side effect of ···【More】
Update: 09 Mar,2026Source: BigbearViews: 94
Enasidenib was developed by Celgene in the United States and approved for marketing by the US FDA on August 1, 2017.Enasidenib (EnglishIndications)Ena···【More】
Update: 09 Mar,2026Source: BigbearViews: 92
Enasidenib is indicated for adult patients with relapsed or refractory acute myeloid leukemia (AML) who have been diagnosed with an isocitrate dehydro···【More】
Update: 09 Mar,2026Source: BigbearViews: 94
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
